AstraZeneca advances by 4% after results and Brilinta ruling
AstraZeneca’s chief executive David Brennan announces a doubling of its share buyback programme. Photograph: Mike Finn-Kelcey/Reuters AstraZeneca investors have received a double dose of good news, following strong first half results and US endorsement of its blood thinning treatment Brilinta. The company said it would double its share buyback this year to bn after a [...]











